Screening for the fragile X syndrome among the mentally retarded: a clinical study. The Collaborative Fragile X Study Group. 1999

B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
Department of Clinical Genetics, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands.

The fragile X syndrome is characterised by mental retardation with other features such as a long face with large, protruding ears, macro-orchidism, and eye gaze avoidance. This X linked disorder is caused by an expanded CGG repeat in the first exon of the fragile X mental retardation (FMR1) gene which is associated with shut down of transcription and absence of the fragile X mental retardation protein (FMRP). Molecular testing is used for detection of patients and carriers of the fragile X syndrome. In a screening programme for the fragile X syndrome in the south west of The Netherlands, 896 males and 685 females with an unknown cause for their mental retardation were scored on seven fragile X features. All were tested by DNA analysis and 11 new cases were diagnosed. The seven item checklist allowed exclusion from further testing in 86% of the retarded males (95% CI 0.83-0.88) without missing either any of the newly diagnosed cases or, in retrospect, any of the 50 previously diagnosed cases known to our department. These results showed that clinical preselection for DNA testing in mentally retarded males is feasible using a simple scoring list, which will increase the efficiency of further testing eightfold.

UI MeSH Term Description Entries
D008297 Male Males
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D010808 Physical Examination Systematic and thorough inspection of the patient for physical signs of disease or abnormality. Physical Exam,Examination, Physical,Physical Examinations and Diagnoses,Exam, Physical,Examinations, Physical,Exams, Physical,Physical Examinations,Physical Exams
D005260 Female Females
D005600 Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226) FRAXA Syndrome,FRAXE Syndrome,Martin-Bell Syndrome,Fra(X) Syndrome,Fragile X Mental Retardation Syndrome,Fragile X-F Mental Retardation Syndrome,Mar (X) Syndrome,Marker X Syndrome,Mental Retardation, X-Linked, Associated With Fragile Site Fraxe,Mental Retardation, X-Linked, Associated With Marxq28,X-Linked Mental Retardation and Macroorchidism,FRAXA Syndromes,FRAXE Syndromes,Fragile X Syndromes,Marker X Syndromes,Martin Bell Syndrome,Syndrome, FRAXA,Syndrome, FRAXE,Syndrome, Fragile X,Syndrome, Marker X,Syndrome, Martin-Bell,Syndromes, FRAXA,Syndromes, FRAXE,Syndromes, Fragile X,Syndromes, Marker X,X Linked Mental Retardation and Macroorchidism
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D018911 Trinucleotide Repeats Microsatellite repeats consisting of three nucleotides dispersed in the euchromatic arms of chromosomes. Triplet Repeats,Repeat, Trinucleotide,Repeat, Triplet,Repeats, Trinucleotide,Repeats, Triplet,Trinucleotide Repeat,Triplet Repeat

Related Publications

B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
November 2000, American journal of medical genetics,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
June 1996, Human genetics,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
January 2002, Acta paediatrica (Oslo, Norway : 1992),
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
May 1991, Clinical genetics,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
July 1999, Clinical genetics,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
January 1992, TSitologiia i genetika,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
January 1997, Annales de genetique,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
January 2000, Annals of Saudi medicine,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
July 2006, Genetics and molecular research : GMR,
B B de Vries, and S Mohkamsing, and A M van den Ouweland, and E Mol, and K Gelsema, and M van Rijn, and A Tibben, and D J Halley, and H J Duivenvoorden, and B A Oostra, and M F Niermeijer
January 2004, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
Copied contents to your clipboard!